Avidin, led by Dr. Liliana Fehér, has developed its own one-step RT-PCR kit, the Cov2QuantTM SARS-Cov-2 Quantification kit (cat: CQ-100), designed to detect the novel corona virus, SARS-Cov-2, quantitatively by using reverse trascription reaction and quantitative real-time polymerase chain reaction.
Hypoxia is a common feature of neurodegenerative diseases, including Alzheimer’s disease that may be responsible for disease pathogenesis and progression.
Avidin has expanded the company’s portfolio with a specialized clinical molecular diagnostics department focused on the detection and monitoring of infectious diseases.
Avidin set up viral diagnostics lab and developed own reagents and method to combat Covid-19 reported by HVG 05/28/2020 Avidin, reported by HVG (Weekly World
Novel SARS-CoV-2 vaccine program 04/07/2020 Avidin´s novel SARS-CoV-2 vaccine program has been funded by National Research, Development and Innovation Office Project identification number: 2020-2.1.1.-ED-2020-00015Project title:
Avidin together with partner Synaptogenex awarded with Market-leaded Research Development and Innovation Support 20.01.2020 Project title: Development, testing and production of active compounds and functional
Molecular sciences publishes Immunomodulatory Effect of Cisplatin explored with Single Cell Mass Cytometry
Avidin demonstrates in Molecular Sciences Immunomodulatory Effect of Cisplatin explored with Single Cell Mass Cytometry 12.25.2019 Single Cell Mass Cytometry Revealed the Immunomodulatory Effect of
Avidin publishes in Molecules the enantioselective synthesis of 8-hydroxyquinoline derivative, Q134 which is a hypoxic adaptation inducer 11.19.2019 Hypoxia is a common feature of neurodegenerative
Unique drug candidate being developed against Alzheimer’s disease reported by PharmaOnline (Hungarian) It has three mechanisms of action on important pathways of Alzheimer’s disease at